Meeting
2013 ASCO Annual Meeting
A novel method to identify and monitor endogenous tumor-reactive T cells by high expression of CD11a (LFA-1) and PD-1 (CD279) as immunologic readout for evaluating the efficacy of PD-1 blockade.
Authors
Haidong Dong
College of Medicine, Mayo Clinic, Rochester, MN
Haidong Dong , Svetomir Markovic , Christopher J Krco , Eugene D. Kwon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Immunotherapy
Track
Developmental Therapeutics
Sub Track
Biomarkers and Correlative Studies from Immunotherapy Trials
Citation
J Clin Oncol 31, 2013 (suppl; abstr 3037)
DOI
10.1200/jco.2013.31.15_suppl.3037
Abstract #
3037
Poster Bd #
13D
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Early response marker during pembrolizumab treatment in metastatic urothelial cancer: Temporal shift in peripheral CD4 T cells expressing chemokine receptors.
First Author: Maud Rijnders
Poster
2020 ASCO Virtual Scientific Program
Investigating the tumor immune infiltrate for populations that predict immune-related adverse events (irAEs) in patients receiving PD-1 inhibitors.
First Author: Steven Michael Blum
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Low-dose IL-12 preconditions the tumor microenvironment to enhance the efficacy of PD-1 blockade.
First Author: C. Marcela Diaz-Montero
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Clinical significance of PD-L1 levels in plasma-derived exosomes in head and neck cancer.
First Author: Marie-Nicole Theodoraki